Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can we decode the hidden subtypes of early Parkinson's?

NCT ID NCT07752355

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This study investigates the biological mechanisms behind young-onset Parkinson's disease, which begins before age 50. Researchers will analyze genetic tests and protein markers in spinal fluid and skin biopsies from 250 participants to identify distinct disease subtypes. The goal is to better understand why the disease develops earlier in some people and to find biomarkers that could help tailor future treatments and clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could identify biological markers and genetic factors that help classify young-onset Parkinson's into subtypes, potentially guiding more personalized treatments and clinical trial design.
What could go wrong
This is an observational study, so it won't directly test a treatment. Findings may not lead to immediate clinical changes, and the biological markers studied may not prove to be reliable indicators across all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Male or Female subjects with Parkinson disease and non-affected subjects 18 years of age or older.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: YOPD cohort: 1. Male or female 18 years or older (inclusive) of any race and ethnicity 2. Diagnosis of Parkinson's disease (PD) confirmed by a movement disorder specialist and with an age of onset of less than or equal to the age of 50 years old 3. Willingness to undergo a skin punch biopsy LOPD cohort: 1. Male or female 18 years or older (inclusive) of any race and ethnicity 2. Diagnosis of PD confirmed by a movement disorder specialist and with an age of onset after the age of 50 years Healthy Control cohort: 1. Male or female 18 years or older (inclusive) of any race and ethnicity 2. Never been diagnosed with PD as reported by medical history and as assessed by study PI Exclusion Criteria: 1. Diagnosis of atypical parkinsonism (i.e. progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy) or secondary parkinsonism (i.e. normal pressure hydrocephalus, drug-induced parkinsonism). 2. Clinical history of autoimmune or chronic inflammatory disorder or exposure to chronic immunosuppressant or immunomodulatory medications. 3. Pregnancy 4. Dermatological conditions that would prevent performing skin punch biopsies

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Late onset Parkinson disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.